Opportunities
Network Survey for Accelerating Medical Device and Diagnostic Reimbursement
As a funder of technology innovation in a vibrant health ecosystem, the Advanced Research Projects Agency for Health (ARPA-H) seeks to provide best-in-class and novel services and partnerships to help accelerate the reimbursement process for innovative medical devices and diagnostics following their authorization from the U.S. Food and Drug Administration (FDA).
To support this effort, the Investor Catalyst Hub is issuing a network survey to collect expert input from medical technology developers and manufacturers, payors, healthcare providers, and other key stakeholders uniquely positioned to provide valuable insights about the reimbursement process. These inputs will help inform ARPA-H on how to close the median reimbursement approval gap for relevant agency-funded efforts from 5.7 years to 2 years.
To learn more about the goals of the network survey, register now to attend a virtual information session led by ARPA-H’s Project Accelerator Transition Innovation Office Scientific Operations Advisor, Arunan Skandarajah, Ph.D. on Friday, January 17, 1:30 – 2:30 p.m. ET.
RNA Biomanufacturing Survey
The potential of RNA vaccines and therapeutics may be accelerated by increased access to affordable, high-quality, and scalable RNA for research and development. Prospective funding partners seek experts to provide key information on RNA market demand and distribution, which will help shape how we address needs and challenges in RNA manufacturing technology and platforms.
ARPA-H wants to hear from scientists who use purified RNA in basic research, vaccine development, and/or therapeutics research. Fill out this survey by January 10, 2025, to share your specific needs and challenges for sourcing high-quality RNA greater than 300 nucleotides.
INDEX
ARPA-H recently launched the ImagiNg Data EXchange (INDEX) program, which aims to revolutionize medical artificial intelligence (AI) tool development. This program was directly informed by the findings of the medical imaging data marketplace network survey that the IC Hub conducted in spring 2024.
ARPA-H Program Manager Ileana Hancu, Ph.D., is hosting a virtual information session on Monday, January 13, 1:00 p.m. ET to provide potential performers with an overview of INDEX, the goals of the program, technical areas of focus, and upcoming deadlines.
OCULAB
ARPA-H’s Ocular Laboratory for Analysis of Biomarkers program seeks to develop a tear-based biomarker measurement system that can be inserted into the tear duct for continuous health monitoring and provide ultra-precise medication dosing for personalized treatment via a closed-loop delivery system. Solution summaries are due January 27, 5:00 p.m. ET.
PRECISE-AI
ARPA-H’s PRECISE-AI (Performance and Reliability Evaluation for Continuous Modifications and Useability of Artificial Intelligence) is focused on developing capabilities to automatically detect and mitigate artificial intelligence (AI) model degradation in clinical settings. The program aims to create tools that can monitor clinical AI model performance, identify when degradation occurs, and provide auto-correction capabilities without requiring human oversight.
PRECISE-AI final Innovative Solutions Opening (ISO) closes January 15, 2025.
ARPA-H HEROES
The ARPA-H HEalth care Rewards to Achieve Improved OutcomES (HEROES) program aims to trial and validate a radically different approach to creating preventative care incentives in the health market. This approach involves offering direct payments to individual “health accelerators”—such as nonprofits or care consortiums—that successfully implement preventative care campaigns that improve the rates for specific health harms in an entire geographic population.
Medical Imaging Data Marketplace—Network Survey
The Advanced Research Projects Agency for Health (ARPA-H) and the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) are partnering to streamline access to affordable, high-quality, regulatory-ready medical imaging data. The agencies are exploring the development of a medical imaging data marketplace (MIDM) to expedite innovation in Software as a Medical Device (SaMD) and other artificial intelligence (AI)/machine learning (ML)-enabled medical devices.
In support of this initiative, the Investor Catalyst Hub issued a Network Survey to collect feedback about specific needs and challenges that medical imaging software and product developers, users of AI and ML medical imaging products, and private and public organizations face with utilizing, managing, and producing data for product development and evaluation.